Zydus Lifesciences Limited (IN:ZYDUSLIFE)
:ZYDUSLIFE
Top Page
Zydus Lifesciences Limited
(ZYDUSLIFE)
Select Model
Select Model
Rating:72Outperform
Price Target:
₹958.00
▲(3.93% Upside)
Action:ReiteratedDate:10/31/25
Zydus Lifesciences' strong financial performance is the most significant factor, supported by robust revenue and profit growth, a healthy balance sheet, and strong cash flow generation. Technical analysis presents mixed signals, with bearish momentum offset by neutral RSI and moving averages. Valuation is fair, with a moderate P/E ratio and dividend yield. The absence of earnings call and corporate events data did not impact the score.
Positive Factors
Sustained Revenue Growth
Consistent high revenue growth (~18.9%) indicates expanding market reach and successful product mix across domestic and international markets. Over 2-6 months this supports reinvestment in R&D, scale benefits in manufacturing, and greater negotiating leverage with payors and suppliers.
Negative Factors
High Total Liabilities Despite Low Leverage
Although leverage ratios are low, an elevated absolute level of total liabilities raises potential contingent and funding risks over time. Large liabilities can stress liquidity during operational setbacks and limit optionality for opportunistic investments or dividend flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Revenue Growth
Consistent high revenue growth (~18.9%) indicates expanding market reach and successful product mix across domestic and international markets. Over 2-6 months this supports reinvestment in R&D, scale benefits in manufacturing, and greater negotiating leverage with payors and suppliers.
Read all positive factors
Zydus Lifesciences Limited (ZYDUSLIFE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹869.64B
Dividend Yield1.19%
Average Volume (3M)33.86K
Price to Earnings (P/E)22.1
Beta (1Y)0.55
Revenue Growth14.01%
EPS Growth14.62%
CountryIN
Employees26,921
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)10.03
Shares Outstanding1,006,234,000
10 Day Avg. Volume33,597
30 Day Avg. Volume33,862
Financial Highlights & Ratios
PEG Ratio1.05
Price to Book (P/B)3.69
Price to Sales (P/S)3.80
P/FCF Ratio17.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,015.00Price Target Upside10.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)40.7
Revenue Forecast (FY)₹288.39B
Zydus Lifesciences Limited Business Overview & Revenue Model
Company Description
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, Latin America, the Asia Pacific, and Africa. The company operates in Pha...
How the Company Makes Money
Zydus Lifesciences makes money primarily by selling pharmaceutical products and related healthcare offerings across domestic and international markets. Key revenue streams include: (1) Finished dosage formulations: Revenue is generated from the ma...
Zydus Lifesciences Limited Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
80
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 244.94B | 232.41B | 195.47B | 172.37B | 151.10B | 144.03B |
| Gross Profit | 161.97B | 167.03B | 131.54B | 107.67B | 94.24B | 94.60B |
| EBITDA | 73.82B | 68.30B | 52.57B | 35.34B | 31.70B | 34.15B |
| Net Income | 49.20B | 45.26B | 38.59B | 19.60B | 44.87B | 21.34B |
Balance Sheet | ||||||
| Total Assets | 468.97B | 372.02B | 292.81B | 257.56B | 277.95B | 238.85B |
| Cash, Cash Equivalents and Short-Term Investments | 70.69B | 78.08B | 13.58B | 11.92B | 35.05B | 11.27B |
| Total Debt | 96.36B | 32.13B | 8.04B | 11.95B | 42.21B | 46.08B |
| Total Liabilities | 188.07B | 108.43B | 71.79B | 60.68B | 87.42B | 89.55B |
| Stockholders Equity | 253.02B | 239.53B | 198.29B | 175.16B | 170.00B | 129.92B |
Cash Flow | ||||||
| Free Cash Flow | 785.00M | 50.64B | 23.21B | 16.58B | 9.02B | 24.39B |
| Operating Cash Flow | 9.46B | 67.77B | 32.28B | 26.89B | 21.04B | 32.93B |
| Investing Cash Flow | -51.93B | -83.72B | -14.75B | 11.71B | -10.00B | -7.22B |
| Financing Cash Flow | 40.45B | 20.14B | -17.79B | -44.00B | -8.68B | -25.49B |
Zydus Lifesciences Limited Technical Analysis
Negative
921.80
Price Trends
897.88
Negative
910.62
Negative
948.08
Negative
Market Momentum
-9.24
Positive
41.35
Neutral
23.72
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ZYDUSLIFE, the sentiment is Negative. The current price of 921.8 is above the 20-day moving average (MA) of 894.40, above the 50-day MA of 897.88, and below the 200-day MA of 948.08, indicating a bearish trend. The MACD of -9.24 indicates Positive momentum. The RSI at 41.35 is Neutral, neither overbought nor oversold. The STOCH value of 23.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ZYDUSLIFE.
Zydus Lifesciences Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ₹869.64B | 22.07 | ― | 1.19% | 14.01% | 14.62% | |
72 Outperform | ₹1.04T | 20.49 | ― | 0.57% | 15.49% | 64.37% | |
70 Outperform | ₹1.02T | 21.88 | ― | 0.63% | 14.10% | 9.72% | |
68 Neutral | ₹964.01B | 45.14 | ― | 0.87% | 6.93% | 21.55% | |
66 Neutral | ₹1.35T | 51.30 | ― | 0.84% | 9.11% | 18.76% | |
59 Neutral | ₹824.60B | 55.46 | ― | 0.04% | 23.22% | -19.19% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:ZYDUSLIFE
Zydus Lifesciences Limited
864.25
-26.59
-2.98%
IN:CIPLA
Cipla Ltd
1,193.40
-285.94
-19.33%
IN:DRREDDY
Dr. Reddy's Laboratories Ltd.
1,217.60
73.60
6.43%
IN:LUPIN
Lupin Limited
2,276.80
195.23
9.38%
IN:MANKIND
Mankind Pharma Ltd.
1,997.45
-429.45
-17.70%
IN:TORNTPHARM
Torrent Pharmaceuticals Ltd
3,989.10
767.54
23.83%
Zydus Lifesciences Limited Corporate Events
Zydus launches reusable multi-dose Semaglutide pen for diabetes and obesity in India
Mar 21, 2026
Zydus Lifesciences has launched Semaglutide Injection in India under the brand names SEMAGLYN, MASHEMA and ALTERME following patent expiry, targeting Type 2 diabetes and obesity. Approved by the Drug Controller General of India, the therapy is pos...
Zydus Lifesciences Publishes Q3 and 9M FY26 Investor Presentation
Feb 9, 2026
Zydus Lifesciences Limited has released an investor presentation detailing its unaudited financial results for the quarter and nine months ended December 31, 2025. The disclosure, made under SEBI’s Listing Regulations and shared with both BS...
Zydus Lifesciences Posts Strong Q3 and 9M FY26 Growth With Higher Margins
Feb 9, 2026
Zydus Lifesciences Limited reported a strong operational performance for the third quarter of FY26, with revenue from operations rising 30% year-on-year to Rs. 68,645 million and EBITDA up 31%, delivering a margin of 26.5%. The company invested Rs...
Zydus Unveils World’s First Nivolumab Biosimilar in India to Broaden Cancer Care Access
Jan 22, 2026
Zydus Lifesciences has launched Tishtha, the world’s first biosimilar of the cancer immunotherapy drug Nivolumab, in the Indian market, reinforcing its capabilities in advanced biologics and immuno-oncology. Offered in 100 mg and 40 mg dosag...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.